Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reelin-immunoreactive neurons in the adult vertebrate pallium.

Journal of chemical neuroanatomy·2001
Same author

Ionic films on vicinal metal surfaces: enhanced binding due to charge modulation.

Physical review letters·2001
Same author

Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis.

The American journal of medicine·2001
Same author

Structure and mesomorphism of neodymium(III) alkanoates.

Inorganic chemistry·2001
Same author

[Trabeculotomy in congenital glaucoma: comparison to goniotomy].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2001
Same author

Specific passive immunity reduces the excretion of glycoprotein E-negative bovine herpesvirus type 1 vaccine strain in calves.

Vaccine·2001

Related Experiment Video

Updated: May 26, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

[Thrombolytic therapy for pulmonary embolism].

G Meyer1

  • 1Service de Pneumologie, Université Paris Descartes, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France. guy.meyer@egp.aphp.fr

Journal Des Maladies Vasculaires
|December 20, 2011
PubMed
Summary

Pulmonary embolism (PE) with shock has high mortality. While thrombolysis may reduce deaths in some PE patients, its use in intermediate-risk cases with right ventricular dysfunction is still debated, pending new trial results.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Related Experiment Videos

Last Updated: May 26, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Area of Science:

  • Cardiology
  • Pulmonology
  • Critical Care Medicine

Background:

  • Pulmonary embolism (PE) with shock presents a high mortality risk (25-50%).
  • Current evidence, primarily from meta-analyses, suggests thrombolysis may decrease mortality in PE patients.
  • However, the benefit of aggressive therapy beyond anticoagulation in hemodynamically stable PE patients is not well-established.

Purpose of the Study:

  • To review the current understanding of pulmonary embolism treatment strategies.
  • To discuss the controversial role of thrombolysis in sub-massive or intermediate-risk PE.
  • To highlight ongoing research addressing treatment efficacy in specific PE patient groups.

Main Methods:

  • Review of existing meta-analyses and recent clinical data on pulmonary embolism.
  • Analysis of risk stratification criteria for intermediate-risk PE, including right ventricular dysfunction and biomarkers.
  • Discussion of the clinical implications of ongoing randomized controlled trials.

Main Results:

  • Thrombolysis may reduce mortality in PE patients, but evidence from large randomized trials is lacking.
  • Hemodynamically stable PE patients generally have lower mortality and may not require aggressive treatment.
  • Sub-massive or intermediate-risk PE, characterized by right ventricular dysfunction or elevated biomarkers (troponin, BNP), presents a complex treatment dilemma.

Conclusions:

  • The role of thrombolytic therapy in intermediate-risk pulmonary embolism remains controversial.
  • Clinical decisions for these patients require careful consideration of risk factors and potential treatment benefits.
  • A large randomized controlled trial is expected to provide further clarity on thrombolysis efficacy in intermediate-risk PE.